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Abstract
Background: Interactions between mononuclear cells and activated pancreatic myofibroblasts
(pancreatic stellate cells; PSC) may contribute to inflammation and fibrosis in chronic pancreatitis
(CP).
Methods: Markers of fibrosis and inflammation were concomitantly analysed by
immunohistochemistry in chronic pancreatitis tissues. In vitro, PSC were stimulated with TNFalpha
and LPS. Primary human blood mononuclear cells (PBMC) and PSC were cocultured, followed by
analysis of cytokines and extracellular matrix (ECM) proteins. PBMC were derived from healthy
donors and CP and septic shock patients.
Results: In areas of mononuclear cell infiltration in chronic pancreatitis tissues, there was
decreased immunoreactivity for collagen1 and fibronectin, in contrast to areas with sparse
mononuclear cells, although PSC were detectable in both areas. LPS and TNFalpha induced
collagen1 and fibronectin levels as well as the matrix degradation enzyme MMP-1. Coculture
experiments with PSC and PBMC revealed increased fibronectin secretion induced by PBMC. In
addition, donor and CP PBMC significantly induced an increase in IL-6, MCP-1 and TGFbeta levels
under coculture conditions. Determination of the source of cytokines and ECM proteins by mRNA
expression analysis confirmed PSC as major contributors of ECM production. The increase in
cytokine expression was PBMC- and also PSC-derived.
Conclusion: Mononuclear cells modulate the activity of pancreatic stellate cells, which may in turn
promote fibrosis and inflammation.
Published: 5 December 2007
Journal of Translational Medicine 2007, 5:63 doi:10.1186/1479-5876-5-63
Received: 1 June 2007
Accepted: 5 December 2007
This article is available from: http://www.translational-medicine.com/content/5/1/63
© 2007 Michalski et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 11
(page number not for citation purposes)
Journal of Translational Medicine 2007, 5:63 http://www.translational-medicine.com/content/5/1/63Background
The exact pathogenesis of chronic pancreatitis (CP) is
unknown, but the disease results from an injury to a pan-
creatic cell population, which then activates pancreatic
stellate cells (PSC) as a final common response. This proc-
ess is associated with excessive accumulation of extracellu-
lar matrix (ECM) proteins by PSC and a massive
infiltration of mononuclear cells [1-6]. Clinically, CP is
accompanied by a severe pain syndrome and by a loss of
pancreatic function (both exocrine and endocrine). PSC
have been determined as the major source of ECM protein
production, and have also been shown to produce
cytokines and chemokines [7-11]. Thus, anti-fibrogenic
therapies aim to reduce the activity of PSC in order to
inhibit the accumulation of ECM proteins and also to pre-
vent digestion of the basement membranes, which allows
PSC to enter inflammatory areas and to excessively
deposit ECM.
In liver cirrhosis, tissue macrophages derived from blood
mononuclear cells have been shown to influence fibro-
genesis by activating hepatic myofibroblasts [12], while
suppression of macrophage infiltration inhibits hepatic
stellate cell activation and thus liver fibrogenesis. During
fibrogenesis, local inflammation may not be initiated by
apoptosis/necrosis of parenchymal cells but by resident
and recruited inflammatory cells; these inflammatory
cells, once in an active state, release cytokines which in
turn activate stellate cells [13,14].
Recent studies have investigated the response of hepatic
stellate cells to lymphocyte subsets, which can be divided
into Th1 and Th2 predominant [15]. Different Th1 or Th2
subsets seem to modulate the fibrotic response towards
anti- or pro-fibrogenesis, thus resulting in an apparent IL-
10 paradox: IL-10 is anti-fibrogenic but is produced dur-
ing a pro-fibrotic Th2 immune response [16]. Mononu-
clear cells within fibrotic areas have been shown to secrete
a wide variety of agents which induce matrix generation/
degradation [17-19], but there are no data on different
responses of PSC to PBMC from various sources – i.e.,
healthy donors and CP patients.
In CP, a generalized immune response has been suggested
due to increased expression of TNFalpha and its receptor
on PBMC and which was associated with PSC cytotoxicity
[20]. Furthermore, it has been shown that LPS-activated
macrophages stimulate the synthesis of ECM proteins by
PSC [21]. In rats, suppression of macrophage infiltration
inhibited activation of hepatic stellate cells [12]. Simi-
larly, it has been shown that both pro- and anti-inflamma-
tory cytokines, such as PDGF and TGFbeta, activate PSC
and thus contribute to pancreatic fibrogenesis [22]. TGF-
beta was subsequently confirmed as a key regulator of
ECM production and PSC proliferation due to its inhibi-
tion of MMPs in an autocrine fashion which enhanced
fibrogenesis by reducing collagen degradation [23].
In terms of transcriptional regulation, nuclear factor kap-
paB (NFkB) is a well-characterized transcription factor
which is activated by oxidative stress or by TNFalpha, and
which activates key anti-fibrotic genes such as MMP-2.
Interestingly, inhibition of NFkB by IkB has been shown
to decrease IL-6 and ICAM-1 levels in rat hepatic stellate
cells during experimental liver injury [24]. Thus in many
ways, lymphocytes modulate fibrogenesis depending on
their activation state, either towards anti- or pro-fibrosis.
Clinically, it is hypothesized that immune suppression
accelerates the development and progression of fibrosis,
underlining the importance of immune regulation for
stellate cell function [25-27].
Understanding the pathobiological mechanisms underly-
ing activation states of immune cells and PSC, as well as
their interactions which are associated with the develop-
ment of chronic pancreatitis, is therefore a prerequisite for
the design of novel therapeutic approaches. Here, we
demonstrate the significance of an interaction between
PBMC and PSC which influences fibrogenesis and inflam-
mation in chronic pancreatitis.
Patients, Materials and Methods
Patients and tissue sampling
Patients with chronic pancreatitis (n = 13), patients with
sepsis (n = 4), and age- and sex-matched healthy adults (n
= 10) were eligible for enrollment in the study. Blood
samples were collected preoperatively from CP patients or
on the intensive care unit from septic shock patients. Tis-
sue samples were collected during pancreatic resections
for CP. These were either immediately processed for isola-
tion of primary human pancreatic stellate cells or snap
frozen at -80°C or formalin fixed and paraffin embedded.
The use of human material for analysis was approved by
the local ethics committee (University of Heidelberg, Ger-
many), and written informed consent was obtained prior
to the operation and the blood sampling.
Immunohistochemistry
Immunohistochemistry was performed as described pre-
viously [28,29]. Briefly, consecutive sections from chronic
pancreatitis patients (n = 10) were stained for collagen1,
fibronectin, alpha-SMA, CD31, CD45 and vimentin. Pri-
mary antibodies against collagen1 (diluted 1:600;
ab6308, Abcam, Cambridge, UK), fibronectin (diluted
1:500; F3648, Sigma Aldrich, Taufkirchen, Germany),
alpha-SMA (diluted 1:500; M0851, DAKO Cytomation,
Hamburg, Germany), CD-31 (diluted 1:50; M0823,
DAKO Cytomation), CD45 (ready to use; N1514, clone
2B11&PD7/26, DAKO Cytomation) and vimentin
(diluted 1:500; M7020, DAKO Cytomation) were appliedPage 2 of 11
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collagen1, alpha-SMA, CD31, CD45, and vimentin and
(anti-rabbit) for fibronectin were purchased from DAKO
Cytomation as EnVision+ ready-to-use solutions.
Human primary PSC and PBMC isolation and culture
Human PSC isolation and culture were performed as
described previously [8,28]. PBMC were isolated from
heparinized blood by ficoll density gradient separation
(Histopaque®-1077, Sigma-Aldrich, Taufkirchen, Ger-
many) as previously described [30].
Treatment of PSC with TNF-alpha and LPS
Sister clones of PSC were treated with TGFbeta1 (5 ng/ml,
GF111 Chemicon Temecula, CA, USA), TNFalpha (1 ng/
ml, GF023 Chemicon Temecula, CA, USA), and LPS (1
ng/ml). Collection of RNA was performed at 6 and 24
hours as described before [31].
Coculture of PSC and PBMC
Primary human PSC were cocultured with freshly isolated
PBMC using cell culture inserts with 1.0 µm pore size
according to the manufacturer's instructions (BD Falcon,
city, NJ, USA). PSC were plated on the bottom of 6-well
cell culture plates at a density of 25,000/cm2 in 3 ml of
DMEM/Ham's F12 in the presence of 10% FCS 24 hours
prior to the onset of coculture. Thereafter, medium was
changed to DMEM/Ham's F12 with 0.5% FCS and freshly
isolated human PBMCs were seeded on the membrane
insert in 2 ml of the same culture medium. The ratio of
PBMC/PSC was 15:1. After overnight incubation (24
hours), the supernatants from PSC and PBMC were mixed
and immediately frozen at -80°C for ELISA experiments;
the cells were processed and frozen at -80°C prior to anal-
ysis by QRT-PCR and immunoblotting.
Quantitative real-time RT-PCR
All reagents and equipment for mRNA/cDNA preparation
were purchased from Roche Applied Science Diagnostics
(Mannheim, Germany). QRT-PCR was performed as
described previously [31]. All primers were obtained from
Search-LC (Heidelberg, Germany).
Immunoblot analysis
For immunoblot analyses of cocultured PSC and PBMC as
well as LPS- or TNFalpha-treated PSC, cells were processed
as described [28,29]. Primary antibodies against collagen
type-1 (diluted 1:2000; sc-28657, Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA), fibronectin (1:10,000; F3648,
Sigma Aldrich, Taufkirchen, Germany), alphaSMA
(1:10,000; M0851, DAKO Cytomation, Hamburg, Ger-
many) and gamma-tubulin as an equal loading control
(1:5,000; sc-7396, Santa Cruz Biotechnology) were
applied overnight at 4°C; secondary antibodies (collagen
type-1 diluted 1:2,000; fibronectin, alphaSMA and
gamma-tubulin diluted 1:5,000) were added for one hour
at room temperature. Densitometry was performed as
described previously [28].
Enzyme-Linked Immunosorbent Assay (ELISA)
To determine levels of MCP-1, IL-6 and TGFbeta in cocul-
ture supernatants, commercial ELISA kits were used
according to the manufacturer's instructions (OptEIA™
ELISA kits for human MCP-1 and IL-6 from BD Bio-
sciences [BD, Heidelberg, Germany]; ELISA DuoSet®
human TGFbeta kit from R&D Systems [R&D, Abingdon,
UK]).
Nuclear extracts and NFkB p65 ELISA
To isolate the nuclear protein fraction and to measure
nuclear NFkB p65 levels, cells were processed after 2 hours
of coculture using a commercial TransAM™ NF-kB family
ELISA-based kit according to the manufacturer's instruc-
tions (Active Motif, Rixensart, Belgium).
Statistical analysis
Statistical analysis was performed using GraphPad Prism
4 Software (GraphPad, San Diego, CA, USA). A paired t-
test was used for analysis of densitometries. The Mann-
Whitney U test was used for comparisons of cytokine lev-
els in cell culture supernatants and for comparisons of
cytokine expression in PBMC. Analysis of variance
(Kruskal-Wallis test) was performed for comparisons of
differences of PSC mRNA expression levels, followed by a
post-hoc Dunn's multiple comparison test. The level of
statistical significance was set at p < 0.05.
Results
Suppression of ECM production in mononuclear cell 
infiltrates in chronic pancreatitis
To judge the pattern of extracellular matrix protein distri-
bution within and in the vicinity of mononuclear cell
infiltrates in human chronic pancreatitis tissues (n = 10),
immunohistochemistry was performed with antibodies
against mononuclear cells (CD45; MNC), activated pan-
creatic stellate cells (alpha smooth muscle actin, alpha-
SMA; vimentin; activated PSC), and the ECM proteins
fibronectin and collagen1. To distinguish between PSC
and small vessels, the endothelial marker CD31 was used.
We then analysed patterns of stellate cells, mononuclear
cells and matrix deposition. Pancreatic stellate cell activity
(alpha-SMA-positive and vimentin-positive cells: Figure
1A &1B; for endothelial staining see Figure 1C) and matrix
deposition were different around different patterns of
mononuclear cell infiltration, namely, around and within
1) clusters (Figure 1D; arrows), 2) loosely distributed
mononuclear cells (Figure 1D; arrowhead) and 3) single
mononuclear cells (Figure 1A–C; arrowheads; PSC:
alphaSMA-positive and vimentin-positive, but CD31-neg-
ative). Activated PSC deposit extracellular matrix (ECM;Page 3 of 11
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expected, PSC are found mainly in areas of inflammation
and ECM deposition (Figure 1A &1B; for endothelial
staining see Figure 1C). Activated PSC were also found
within clusters of mononuclear cells (Figure 2A &2D,
arrows; Figure 2B &2C, corresponding vimentin and
CD31 stainings) and, therefore, one might expect deposi-
tion of ECM within these clusters but none is seen (Figure
2E &2F, arrows) suggesting mononuclear cell suppres-
sion. These findings are corroborated by further immuno-
histochemistries showing that in areas of loosely
distributed/single mononuclear cells (Figure 1G, arrows),
there is only faint collagen1 and fibronectin staining (Fig-
ure 1H &1I, arrows). However, in areas without mononu-
clear cells (Figure 1G, dotted arrows), there is strong ECM
protein staining (Figure 1H &1I, dotted arrows).
LPS and TNFalpha modulate PSC activity
The effects of pro-inflammatory substances on the activa-
tion state of PSC were examined by incubation with
Immunohistochemistry of human chronic pancreatitis tissue specimensFigure 1
Immunohistochemistry of human chronic pancreatitis tissue specimens. Consecutive sections of chronic pancreati-
tis tissues were subjected to immunohistochemistry using antibodies against alphaSMA (A; SMA), vimentin (B; VIM), CD31 (C), 
CD45 (D), collagen1 (E; COL) and fibronectin (F; FBN). Arrows: area around packed clusters of mononuclear cells. Arrow-
heads in A-C: pancreatic stellate cells (SMA- and VIM-positive, CD31-negative). Arrowhead in D: loosely distributed area of 
mononuclear cell infiltration. Arrowhead in E&F: areas of less intense immunoreactivities for collagen1 and fibronectin. Dotted 
arrows: Areas of strong collagen1 and fibronectin staining. Original magnification: ×50. (G) Arrows: areas of loosely distrib-
uted/single mononuclear cells, dotted arrows: area without mononuclear cells. (H&I) Arrows/dotted arrows: corresponding 
areas to (G).
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[28], analysis of "functional" ECM proteins can be per-
formed on cell culture supernatants. This revealed that
TNFalpha and LPS exerted similar effects on PSC. Immu-
noblot analysis of cell culture supernatants was used to
analyze the secretion of the extracellular matrix proteins
collagen1 and fibronectin by PSC. These experiments
showed that both LPS and TNFalpha increased the secre-
tion of collagen1 and fibronectin (Figure 3A). Further-
more, the matrix degradation enzyme MMP-1 was
induced (LPS by 46%; TNFalpha by 454%), while its
inhibitor TIMP-2 was suppressed (by 20% and 18%,
respectively; data not shown). Densitometry adjusted to
control PSC supernatants revealed that LPS increased col-
lagen secretion (Figure 3A, p < 0.001) and induced a trend
towards increased fibronectin levels (Figure 3A). TNFal-
pha induced an increase in collagen1 (p = 0.069) and an
increase in fibronectin levels (p = 0.007).
In vitro increase of ECM production is induced by PBMC
To evaluate whether mononuclear cells alter ECM secre-
tion of cultured primary human PSC in vitro, a co-culture
system with PBMC in the upper chamber and PSC in the
lower chamber was used. Cytotoxicity and immunologi-
cal incompatibilities were excluded due to spatial distance
between the cells in the co-culture chambers. Here, PBMC
derived from healthy donors led to a 71% increase in PSC
fibronectin levels after 24 hours of co-incubation (Figure
4B). Using CP PBMC, this effect was more pronounced,
with a 126% increase in fibronectin, whereas in septic
shock PBMC there was a 104% increase (Figure 4B). To
assess whether these effects were dependent on TGFbeta,
its levels in cell culture supernatants were analyzed by
ELISA. These experiments revealed significantly increased
TGFbeta levels (by 130%, 185% and 204%, respectively)
following coculture with donor, CP and sepsis PBMC (Fig-
ure 4A; p < 0.0001, p = 0.0002 and p = 0.0004, respec-
tively).
Coculture of PSC and PBMC induces cytokine secretion
To determine the potential of PSC and PBMC in coculture
to produce cytokines and chemokines, IL-6 and MCP-1
levels were determined in cell culture supernatants (Figure
4A). Following coculture with donor, CP and sepsis
Details of immunohistochemical analysis of chronic pancreatitis tissuesFigure 2
Details of immunohistochemical analysis of chronic pancreatitis tissues. (A&B) Pancreatic stellate cells are seen 
within clusters of mononuclear cell infiltration. (A) Arrows: stellate cells. (C) To exclude that alphaSMA- (SMA) and vimentin-
positive (VIM) structures are endothelia, CD31 staining was performed. (D-F) In areas of loosely packed mononuclear cells 
(arrowhead in D) and packed mononuclear cells (white arrow in D), there is sparse immunoreactivity for collagen1 (arrow-
head and white arrow in E) and moderate staining for fibronectin (arrowhead and white arrow in F). In areas with a low 
number of CD45-positive mononuclear cells (dotted arrow in D), the staining intensities for collagen1 (dotted arrow in E; 
COL) and fibronectin (dotted arrow in F; FBN) are stronger. Original magnification: ×200.
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supernatants was observed (by 553%, 531% and 124%,
with p < 0.0001, p < 0.0001 and p = 0.007, respectively).
A similar effect was seen for MCP-1, with significant
induction following coculture with donor (390%
increase) and CP (370% increase) PBMC (Figure 4A; both
p < 0.0001). However, coculture of PBMC derived from
sepsis patients with PSC did not alter IL-6 levels (Figure
4A; p = 0.1).
Both PBMC and PSC contribute to increased cytokine 
levels
Cytokine and chemokine mRNA expression levels were
subsequently evaluated in PBMC and PSC to determine
the source of increased cytokine/chemokine levels in cell
culture supernatants. Altogether, there was an increase in
cytokine mRNA expression which was more pronounced
in PSC than in PBMC (Figures 5 &6). Analysis of PBMC
mRNA expression confirmed the results of the ELISA rea-
douts. Coculture increased IL-6 expression in donor
PBMC by 400% (Figure 5; p = 0.005), whereas for CP
PBMC there was only a trend towards increased IL-6 levels
following coculture (Figure 5; p = 0.186). In contrast to
ELISA results, sepsis PBMC did not increase IL-6 at the
mRNA level. MCP-1 expression was induced by PBMC
coculture with donor, CP and sepsis PBMC (Figure 5; p =
0.0003, p = 0.006 and p = 0.016, respectively). Following
coculture with donor and CP PBMC, expression levels of
IL-6, MCP-1 and IL-8 were increased in PSC (Figure 6A; all
p < 0.05). However, sepsis PBMC did not induce cytokine
mRNA expression significantly, although a trend toward
an increase was seen (Figure 5A; all p > 0.05).
Increased ECM protein secretion is not accompanied by 
increased transcription
A potential influence of late changes in mRNA transcrip-
tion (24 hours) on the increase of ECM proteins in cocul-
ture and the contributing source of these proteins (PSC
and/or PBMC) was examined using quantitative RT-PCR.
Low-level expression of collagen1 and fibronectin was
unaltered in PBMC following coculture (data not shown).
TGFbeta expression in PBMC was also unchanged after
coculture (Figure 5; p = 0.988, p = 0.3 and p = 0.214,
respectively). Analysis of collagen1 and fibronectin
mRNA in control and cocultured PSC revealed no changes
in expression levels (Figure 6B). Furthermore, TGFbeta
expression also remained unchanged after coculture (Fig-
ure 6A). Thus, the effect of coculture on ECM protein pro-
duction seems to be rather independent of the
transcription of the respective mRNA moieties, but may
involve changes in protein processing/sorting or protein
secretion.
NFkappaB is not involved in signal transduction induced by 
coculture
NFkappaB levels in the nuclear fraction of PSC and PBMC
were determined after two hours of coculture to evaluate
potential rapid effects on the transcriptional level. How-
ever, there was no difference in NFkappaB transactivation
when comparing PBMC and PSC alone with cells in coc-
ulture (data not shown).
Immunoblot of PSC cell culture supernatants and cell lysatesFigure 3
Immunoblot of PSC cell culture supernatants and cell lysates. Cell culture supernatants and cell lysates of vehicle-, 
TGFbeta-, LPS- and TNFalpha-treated PSC were subjected to SDS-PAGE followed by incubation with (A; supernatants) anti-
collagen1 and anti-fibronectin antibodies or (B; cell lysates) an anti-gamma-tubulin antibody Densitometry is shown in percent 
of vehicle-treated control PSC supernatants; n.s. = statistically not significant.
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An important finding of this study is that PBMC-derived
substances alter the phenotype of PSC towards a more
pro-fibrogenic and pro-inflammatory cell-like phenotype
and away from the typical myofibroblast phenotype. This
assumption is underlined by increased ECM protein secre-
tion in TNFalpha- and LPS-treated PSC and a concomitant
increase in collagen1 and fibronectin as well as in pro-
inflammatory cytokines IL-6 and MCP-1 following cocul-
ture of PSC with PBMC.
Progression of fibrosis in chronic pancreatitis is accompa-
nied by inflammation and a severe pain syndrome which
represents a major clinical challenge [1,9,32,33].
Recently, stellate cells themselves have emerged as inflam-
matory effectors [34,35]. Upon activation, they release a
wide variety of chemokines and cytokines and upregulate
the expression of key inflammatory markers [32,36,37].
Since mononuclear cell infiltration is a feature shared by
a variety of fibrotic diseases, increasing attention is being
paid to investigating the role of immune cells in regula-
tion of stellate cell activity [38,39]. Potential activators of
PSC include factors such as cytokines and growth factors
[40]. Activated PSC, in turn, produce autocrine factors
such as periostin and TGF-β which perpetuate their activa-
tion [28].
In our study, immunohistochemical analyses showed an
influence of mononuclear cell infiltrates on PSC: There
was a strong deposition of ECM proteins around the clus-
ters of immune cells and in areas where immune cells
were scarcely distributed in the stroma. On the contrary,
within the packed immune clusters, there was weak
(fibrononectin) or almost absent (collagen 1, alphaSMA)
immunopositivity. These observations might contradict
our in vitro data but could also be explained by increased
Analysis of PSC supernatants and cell lysates following coculture with PBMCFigure 4
Analysis of PSC supernatants and cell lysates following coculture with PBMC. (A) PSC cell culture supernatants 
were subjected to ELISA following coculture with donor, CP and sepsis PBMC. Hatched bars: PSC supernatants. White bars: 
Pooled donor, CP or sepsis PBMC and corresponding PSC supernatants. Black bars: coculture supernatants. *p < 0.05 as 
assessed using the Mann-Whitney U test. (B) Immunoblot analysis of fibronectin in PSC cell lysates. Densitometry shown as 
percent of control adjusted to the corresponding gamma-tubulin density.
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Messenger-RNA expression levels in single-cell and cocultured PBMCFigure 5
Messenger-RNA expression levels in single-cell and cocultured PBMC. PSC alone (without PSC; white bars) and coc-
ultured (with PSC; black bars) PBMC were analyzed by quantitative RT-PCR using primers for IL-6, MCP-1 and TGFbeta. 
Results are expressed as copies per 10 k copies of cyclophilin B (cpb). *p < 0.05 as assessed using the Mann-Whitney U test.
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Messenger-RNA expression levels in single-cell and cocultured PSCFigure 6
Messenger-RNA expression levels in single-cell and cocultured PSC. PSC alone (without PBMC; white bars) and coc-
ultured (with PBMC; black bars) PSC were analyzed by quantitative RT-PCR using primers for IL-6, MCP-1, IL-8 and TGFbeta 
(A) as well as for collagen1 and fibronectin (B). Results are expressed as copies per 10 k copies of cyclophilin B (cpb). *p < 0.05 
as assessed using the Kruskal-Wallis test followed by Dunn's post-hoc test to compare single-cell PSC with cocultured PSC.
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Moreover, this site specific variance in ECM deposition
can be due to the following reasons: 1) The packed
immune clusters are actually forming in expanded
perivascular spaces as hinted by the presence of central
CD31 positive endothelial cells; 2) In vitro, the matrix
degradation enzyme MMP-1 was increased together with
an increase in ECM proteins collagen1 and fibronectin; 3)
High amounts of TNFalpha exert cytotoxic effects on PSC
[20] which is probably represented in vivo as a function of
their density. Using immunohistochemistry, different
phases of immune reaction in the pancreas were seen: in
scarred areas where ECM has replaced parenchymal cells,
there was also a decline in alphaSMA-positive cells
whereas a large number of activated PSC were seen
around injured acini and remaining ducts. We have previ-
ously shown that periostin, which sustains stellate cell
activity, is mostly secreted by PSC around degenerating
acini/tubular complexes [28], possibly marking the inva-
sive front of the activated stroma where newly deposited
ECM gradually replaces the functional parenchyma. These
results are compatible with recent reports which observed
that at the end of tissue repair, the reconstructed ECM
takes over the mechanical load and myofibroblasts disap-
pear by induction of apoptosis [41]. Our current results
underline the change in PSC phenotype towards a more
fibroblast-like cell type with immunologic function.
Recently, it has also been shown for hepatic stellate cells
that natural killer cells and CD4 T cells may induce anti-
fibrosis, whereas CD8 cells are rather pro-fibrotic [42].
Furthermore, cell-to-cell contact of stellate and immune
cells seems ultimately not to be necessary to induce such
effects, since the results of our coculture set-up point out
the importance of secreted mediators. However, our find-
ings may also be due to several other factors: first, we used
PBMC, which have only been in direct contact with the
inflamed pancreas to a very minor extent; second, upreg-
ulation of PSC-produced ECM proteins seems to be a
function of PBMC in general, not particularly of PBMC
which are derived from CP patients; and third, our study
addresses interactions of PBMC and PSC in an artificial
set-up which may reflect the experimental processing of
both PSC and PBMC. Particularly, while there was a ten-
dency towards an increase in fibronectin production fol-
lowing PSC co-culture with CP and septic shock PBMC,
this increase could also have been due to activation of PSC
under culture conditions (plastic cell culture dishes which
lead to activation of PSC).
In terms of cytokine upregulation by PBMC, coculture
seems to be a valid model: it shows that the capacity of
PSC to secrete cytokines may be further increased and may
thus contribute to the ongoing inflammation in chronic
pancreatitis. Interestingly, PBMC derived from septic
shock patients lost the ability to induce PSC cytokine
expression and secretion which may be due to several rea-
sons. It has been reported that there is a general paralysis
of the immune system in sepsis [43-45]. It also seems pos-
sible that – due to the strong acute inflammation in sepsis
patients – the PBMC activity state has been suppressed.
Thus, the secreted mediators which induce PSC activity
may be suppressed in this state. There is also an inverse
regulation of IL-6 and MCP-1 mRNA induction by PBMC
derived from different sources: while the increase in IL-6
expression on the mRNA level was only seen in PBMC
from healthy donors, MCP-1 was significantly induced in
cocultured PBMC from donors, CP and septic shock
patients. The levels of the respective proteins in the super-
natants did not reflect the mRNA regulation, which may
be due to accumulation in the coculture set-up and the
fact that the levels in the supernatants are a result of con-
tributions by both PBMC and PSC.
In conclusion, our study underlines that an interaction
between mononuclear cells and pancreatic stellate cells
may contribute to the vicious cycle of inflammation and
uncontrolled scarring in chronic pancreatitis.
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